Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 29, 2026 08:21 ET | Source: Moleculin Biotech, Inc.

Moleculin Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits

Independent Cleveland Clinic Cardiac Review Supports Potential Best-in-Class Safety Profile as MIRACLE Phase 2b/3 Trial Advances HOUSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc.,...